Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The High affinity immunoglobulin epsilon receptor subunit gamma (FCER1G) is a critical signaling adaptor protein that serves as the functional subunit for the high-affinity IgE receptor (FcεRI) and several other Fc receptors, including FcγRI, FcγRIII, and FcαRI (UniProt: P30273). It exists as a disulfide-linked homodimer that lacks an extracellular ligand-binding domain but contains a vital immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic tail (NCBI Gene: 2207). Upon the binding of IgE-antigen complexes to the alpha subunit of the receptor, the ITAMs in the gamma chain are phosphorylated by Src-family kinases, which then recruit and activate Syk kinase to initiate downstream signaling (PubMed: PMID 10946252). This process is essential for the degranulation of mast cells and basophils, leading to the release of inflammatory mediators like histamine. Beyond allergic responses, FCER1G is involved in various immune processes such as phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) in myeloid cells. Because it is a shared component of multiple immune receptors, it represents a central node in inflammatory signaling and a significant target for therapeutic intervention in allergic and autoimmune diseases (PubMed: PMID 30103468). Current drugs typically target the associated ligands or downstream kinases rather than the gamma chain directly, but its role remains central to the efficacy of these treatments.
The mechanism of action for drugs interacting with this target pathway involves the prevention of IgE binding to the FcεRI complex or the inhibition of downstream signaling components, such as Syk kinase, which are recruited by the phosphorylated ITAMs of the FCER1G subunit (PubMed: PMID 30103468).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High affinity immunoglobulin epsilon receptor subunit gamma (FCER1G) (FCER1G).